Handa Therapeutics LLC.: Handa Therapeutics Acquires FDA Approved Chronic Myeloid Leukemia Drug, PHYRAGO Tablets
PHYRAGO Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa Pharmaceu ...
PharmiWeb11h
Handa Therapeutics Acquires FDA Approved Chronic Myeloid Leukemia Drug, PHYRAGO (dasatinib) Tablets
PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa ...
Medscape1d
Gaviscon® vs. Omeprazole in Symptomatic Treatment of Moderate Gastroesophageal Reflux
Alginates also have proven efficacy. The aim of this trial was to compare short-term efficacy of an alginate (Gaviscon®, 4 × 10 mL/day) and omeprazole (20 mg/day) on GERD symptoms in general ...